20
Participants
Start Date
March 31, 2016
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
Emervel Classic
Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
Emervel Deep
Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
Arthur Swift Research Inc., Montreal
Lead Sponsor
Galderma R&D
INDUSTRY